DMAARNasdaqBlank ChecksUS GAAP · USD

Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. is a Cayman Islands special purpose acquisition company formed to complete a merger or similar business combination. It raised capital through an IPO and private placement and is currently searching for a target, with a stated focus on the pharmaceutical industry.

Ask about the company
Operating profit (EBIT)-2.8m USD
Net income5.9m USD
+2,222.8 %y/y

Fiscal year 2025 · change from previous year

Development 2024–2025

-3-2-10m USD20242025: EBIT -2.8 m USD2025-2.8
RevenueOperating profit (EBIT)

Business

Share of revenue
SPAC capital vehicle100 %

Publicly listed blank check structure used to raise cash for a future acquisition.

Customers

The company does not sell products or services to operating customers; its capital providers are public shareholders, the sponsor, and the underwriters. Its practical counterparties are target companies and their owners, which it seeks to acquire through a business combination, especially in pharmaceuticals. Investor demand is driven by the SPAC structure, redemption rights, and the potential for a future acquisition transaction.

Public IPO investors

Buy units for trust-account exposure, redemption rights, and upside from a future deal

Sponsor

Provides private placement capital and initial support to fund the SPAC structure

Underwriters

Distribute the IPO units and receive underwriting fees tied to the offering

Acquisition targets

Pharmaceutical or other businesses that may be acquired in the initial business combination

Strategy

The company’s near-term strategy is to identify and complete an initial business combination before the mandatory liquidation deadline. Management has stated a preference for pharmaceutical targets, which narrows the search and may improve sector fit and diligence focus. Until a transaction closes, the business is focused on preserving trust capital, managing public-company costs, and maintaining deal optionality.

Identify a suitable pharmaceutical targetShort term

The company has stated a sector focus, which should improve sourcing and diligence quality.

Complete the initial business combinationShort term

The SPAC has no operating business until a transaction closes, so execution is existential.

Manage dilution and transaction economicsMedium term

Redemptions, deferred underwriting fees, and sponsor economics affect the value of the deal.

Geography

The company is incorporated in the Cayman Islands but is managed from the United States and listed through a U.S. capital markets process. Its economic exposure is primarily U.S.-based because the IPO proceeds are held in trust and invested in U.S. government treasury obligations, while the search for a target may extend to any geography. No operating revenue is generated yet, so geography mainly matters through listing venue, legal domicile, and where a future target may operate.

Risks

The company faces the core SPAC risk that it may fail to identify and close a suitable business combination before liquidation. Because it has no operating business or revenue, its value depends almost entirely on transaction execution, while public-company and diligence costs continue to accumulate. It also faces industry-typical risks around target quality, shareholder redemptions, and the possibility that a pharmaceutical acquisition may prove difficult to source or integrate.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Failure to complete an initial business combination1Going concern / liquidation deadline2Shareholder redemptions3Target sourcing and diligence risk4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Failure to complete an initial business combinationImpact: CriticalLikelihood: High

    The company has no operating business and must close a transaction within the combination period or liquidate.

    Exposure: All equity value depends on execution of the deal.

  2. Going concern / liquidation deadlineImpact: CriticalLikelihood: High

    Mandatory liquidation provisions create substantial doubt if a transaction is not completed in time.

    Exposure: Corporate survival as a going concern.

  3. Shareholder redemptionsImpact: HighLikelihood: High

    Public investors can redeem shares, reducing cash available to fund the acquisition.

    Exposure: Transaction size and post-deal capitalization.

  4. Target sourcing and diligence riskImpact: HighLikelihood: High

    The company intends to focus on pharmaceuticals, which can narrow the opportunity set and increase diligence complexity.

    Exposure: Deal pipeline and closing probability.

Accounting

Judgemental items
Redeemable ordinary shares

Remeasurement to redemption value creates large equity adjustments unrelated to operations.

Impact: Affects balance sheet classification and reported equity.

Trust account interest income

Interest on U.S. Treasury investments is the main recurring income before a business combination.

Impact: Drives interim net income despite no operating revenue.

Deferred underwriting commissions

These fees become payable only if a business combination is completed.

Impact: Affects transaction economics and future cash available to the combined company.

Offering costs and sponsor financing

IPO-related costs, private placement proceeds, and related-party notes are central to SPAC accounting.

Impact: Influences equity, cash flow, and reported transaction costs.

Similar listed companies

Publicly listed companies with a comparable business focus.

Drugs Made In America Acquisition II Corp.

DMII · Blank Checks

FACT II Acquisition Corp

FACTW · Aircraft Parts & Auxiliary Equipment, NEC

Translational Development Acquisition Corp.

TDACW · Blank Checks

Fifth Era Acquisition Corp I

FERA · Blank Checks

Columbus Acquisition Corp/Cayman Islands

COLAU · Blank Checks

Safeguard Acquisition Corp.

SAC · Blank Checks

Last updated: 24/09/2026